For the treatment of patients in severe cardiac failure, large oral doses of potassium supplements are required to replace the potassium-wasting effect of diuretic. The ideal potassium preparation has not yet been found. For maximum utilization of the potassium, Kassirer et al. (I965) emphasize that it should be given as the chloride salt, but the ulcerating effect of potassium chloride on the small intestine has been widely recognized (Allen et Two days after resuming oral therapy with digoxin o025 mg., frusemide 40 mg. b.d., and 'Slow K' I200 mg. q.d.s., she complained of difficulty in swallowing one of the 'large yellow tablets' which she said she could feel sticking in her chest. This feeling persisted and severe retrosternal pain ensued. The dysphagia and pain were so intense after taking her tablets the following moming that an emergency barium swallow was carried out.
The barium swallow (Fig. i) showed a persistent filling defect in the lower third of the oesophagus just above the cardiac impression. The defect had the appearance of an impacted tablet and barium was seen to flow readily past it.
Oesophagoscopy, some five hours later, showed an area of mucosal ulceration on the posterior wall ofthe lower third of the oesophagus filled with and surrounded by white powder. There was intense spasm below the ulcerated area. Oesophageal lavage was carried out. A naso-gastric tube was inserted and feeding was entirely by tube for the next five days. No further 'Slow K' was given and potassium supplement as effervescent B.P.C. was substituted. The patient's dysphagia resolved and before discharge a repeat barium swallow showed only the atrial impression at the lower end of the oesophagus: there was no evidence of stricture or ulceration. Discussion Potassium supplements are usually necessary when a patient with heart disease is being treated with diuretics. There is strong evidence that potassium should be given as the chloride salt (Kassirer et The combination of potassium chloride with a slow release core, 'Slow K', has done much to overcome the dangers of potassium therapy and no cases of ulceration of the gastro-intestinal tract have been reported until now. The patient described here, however, provided visible evidence of oesophageal ulceration in association with slow release potassium. The, probable sequence of events was that the tablets were held up in the oesophagus at the level of the large left atrium (Fig. 2) , and the continued action of the preparation on one localized area of mucosa over a period of 48 hours produced ulceration. The finding at oesophagoscopy of an ulcerated area with powder in and around it is strong evidence implicating the potassium salt as the causative agent.
Therapy with slow release potassium in the form of 'Slow K' has been remarkably trouble-free but the present case gives a warning that in circumstances predisposing to oesophageal stasis, ulceration may be produced. Fortunately, the patient's ulceration was detected before grave damage resulted. The patient is now taking effervescent potassium and has no symptoms to suggest residual ulceration or stenosis.
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